Hematopoietic Stem Cells: Overview, Bone Marrow Failure Syndromes, and Pure Red Cell Aplasia

Hematopoietic Stem Cells and Hematopoiesis: Overview

Hematopoietic stem cells (HSCs) reside in the bone marrow and are defined by two properties: self-renewal and multipotency. As multipotent cells, HSCs give rise to progenitor cells, which in turn produce all the mature blood elements — leukocytes, erythrocytes, and platelets. This orderly proliferation and differentiation, termed hematopoiesis, is tightly regulated by the bone marrow microenvironment and by hematopoietic growth factors: erythropoietin (EPO) drives erythrocyte production, thrombopoietin (TPO) drives platelet production, and granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor drive granulocyte, monocyte, basophil, and eosinophil production.

Disorders of hematopoiesis can arise at the HSC or progenitor cell level and can produce either underproduction or overproduction of blood cells. In general, disorders developing from early precursors behave more aggressively than those arising from differentiated cells. Bone marrow failure syndromes are defined by the inability of hematopoiesis to keep pace with physiologic demand for blood cell production (ineffective hematopoiesis), resulting in peripheral cytopenias. Rare inherited (constitutional) causes exist, but acquired disorders are far more common — either from intrinsic marrow disorders such as myelodysplastic syndromes (MDS) or from extrinsic insults such as toxins and autoimmunity, as in aplastic anemia (AA).

Bone Marrow Failure Syndromes: Aplastic Anemia

Definition and Severity Criteria

AA is an acquired HSC disorder characterized by severely decreased bone marrow cellularity and pancytopenia. Although classified as an "anemia," patients typically have the combination of anemia, neutropenia, and thrombocytopenia. Marrow cellularity normally declines with age as fat content rises; in AA this process is dramatically amplified, and the marrow space is largely replaced by fat.

AA is categorized as severe or very severe based on marrow cellularity and the depth of the cytopenias. Severe disease classically requires hypocellular marrow plus at least two of three blood-count criteria: absolute neutrophil count (ANC) <500/μL, platelet count <20,000/μL, and corrected reticulocyte count <1% (or absolute reticulocyte count <60,000/μL); very severe disease is marked by more profound neutropenia (ANC <200/μL). In the modern treatment era, absolute reticulocyte (>25,000/μL) and lymphocyte (>1000/μL) counts are better predictors of response to immunosuppressive therapy and long-term outcome.

Etiology

AA results from a critical reduction in the stem cell pool through autoimmunity, toxins, or infections:

• Medications — antithyroid drugs (methimazole, propylthiouracil), β-lactam antibiotics, sulfonamides, NSAIDs, anticonvulsants (phenytoin, carbamazepine), and gold salts are classically implicated; chloramphenicol, allopurinol, and penicillamine carry more consistent associations in large studies. Discontinuing the offending drug usually allows recovery, but counts may take many weeks to improve.
• Chemicals and radiation — benzene (often an occupational solvent exposure) is the prototypical chemical cause; marrow aplasia is also a predictable consequence of high-dose radiation.
• Viruses — Epstein-Barr virus, HIV, parvovirus B19, and especially seronegative hepatitis.
• Autoimmunity — most "idiopathic" AA is T cell–mediated immune destruction of stem cells; AA may rarely accompany eosinophilic fasciitis, thymoma, or systemic lupus erythematosus.
• Pregnancy — AA very rarely complicates pregnancy and may resolve with delivery.

Incidence is about 2 cases per million annually in Europe and Israel and 5–7 per million in parts of Asia, affecting men and women equally with a biphasic age distribution (major peak in teens/twenties, second peak in older adults).

Inherited Bone Marrow Failure Syndromes: When to Suspect Them in Adults

Although classical inherited syndromes present in childhood, several can surface as marrow failure in an otherwise normal-appearing adult — and recognizing them changes management (donor selection, transplant conditioning, family screening). The major entities:

• Fanconi anemia — an autosomal recessive defect in DNA interstrand cross-link repair (≥23 genes; FANCA most common). Features include short stature, café au lait spots, thumb/radial and genitourinary anomalies, progressive pancytopenia, and increased malignancy risk. Diagnosis is by chromosome breakage studies (diepoxybutane or mitomycin C).
• Telomere biology disorders / dyskeratosis congenita — mutations in telomerase complex genes (TERT, TERC; X-linked DKC1) or shelterin proteins (e.g., TINF2) impair telomere maintenance. The pediatric syndrome carries the triad of oral leukoplakia, dystrophic nails, and reticular hyperpigmentation with early AA. In adults, presentation is not unusual: moderate, sometimes chronic non-progressive AA, isolated macrocytic anemia, or thrombocytopenia — often without physical anomalies.
• Shwachman-Diamond syndrome — a ribosomopathy (usually compound heterozygous SBDS mutations) presenting early in life with neutropenia, pancreatic insufficiency, and malabsorption.
• Germline predisposition syndromes — GATA2 deficiency and familial RUNX1 disorders can present as marrow failure or leukemia predisposition in adults; a family history of unusual infections and warts suggests GATA2 deficiency.

Pathophysiology and the PNH Connection

In immune AA, activated cytotoxic T-cell clones target hematopoietic stem cells; type 1 cytokines (notably interferon-γ) induce Fas expression on CD34+ cells and trigger apoptosis. The stem cell pool in severe disease at presentation may be reduced to ≤1% of normal. Genetically determined features of the immune response likely explain why a common exposure (a drug, seronegative hepatitis) triggers sustained autoimmunity in only a few individuals.

AA is intimately linked to paroxysmal nocturnal hemoglobinuria (PNH). An acquired PIG-A mutation in an HSC produces progeny lacking glycosylphosphatidylinositol-anchored surface proteins, including the complement-stabilizing proteins CD55 and CD59. Sensitive flow cytometry detects a PNH clone in one-half or more of AA patients at presentation, and PNH clones are seen almost exclusively in immune marrow failure.

Clinical Features and Diagnosis

AA can begin abruptly or insidiously. Bleeding is the most common early symptom — days to weeks of easy bruising, gum or nasal oozing, menorrhagia, petechiae. Anemia symptoms (fatigue, weakness, dyspnea, pounding in the ears) are frequent. Infection is an uncommon presenting symptom (in contrast to agranulocytosis), and patients often look remarkably well despite drastically reduced counts; systemic complaints and weight loss should point toward other diagnoses. On examination, petechiae, ecchymoses, pallor, and retinal hemorrhages are typical — but lymphadenopathy and splenomegaly are highly atypical of AA.

Diagnostic evaluation includes:

• Peripheral blood — large erythrocytes (MCV commonly increased), reticulocytopenia, paucity of platelets and granulocytes. Immature myeloid forms suggest leukemia or MDS; nucleated RBCs suggest fibrosis or marrow invasion.
• Bone marrow biopsy — the cornerstone. The biopsy (ideally >1 cm) shows mainly fat, with hematopoietic cells occupying <25% of the marrow space; megakaryocytes are greatly reduced or absent. Residual hematopoietic cells have normal morphology apart from mild megaloblastic erythropoiesis.
• Ancillary studies — PNH clone by flow cytometry; cytogenetics of marrow cells (usually normal in typical AA); chromosome breakage studies and telomere length in children and younger adults; and germline bone marrow failure gene panels when clinical suspicion or family history warrants.

AA must be distinguished from the hypoplastic variant of MDS, which also shows decreased marrow cellularity. Findings favoring MDS include dysplastic cells and cytogenetic abnormalities typical of MDS; patients with hypoplastic MDS are often treated with immunosuppressive therapy as well. (MDS is covered in detail in a later lesson.)

Treatment

Asymptomatic patients with mild to moderate AA can be closely monitored without immediate treatment. For severe disease, the two definitive strategies are replacing the defective stem cells (allogeneic HSCT) or suppressing the immune attack to allow residual marrow to recover.

• Younger patients (<50 years) with a suitable (HLA-matched sibling) donor are usually treated with allogeneic HSCT as first-line therapy; long-term survival exceeds 90% in children and 80% in young patients with a good risk profile. HLA typing should be ordered as soon as the diagnosis is established, and transfusions from family members should be avoided in transplant candidates to prevent sensitization.
• Patients older than 50, or those without a suitable donor, receive immunosuppressive therapy (IST): antithymocyte globulin (ATG) + cyclosporine + prednisone + eltrombopag. This "triple-plus" regimen induces hematologic recovery in 70–80% of patients.

Practical points on the IST regimen:

• ATG product matters: horse ATG is given as intravenous infusions over several days in hospital and is the preferred first-line product; rabbit ATG is substantially less effective, possibly because it also depletes regulatory T cells. Serum sickness (fever, rash, arthralgias) typically appears ~10 days after starting ATG; short-course methylprednisolone is co-administered to blunt this reaction.
• Cyclosporine is started at a high dose and adjusted to blood levels; watch for nephrotoxicity, hypertension, and seizures.
• Eltrombopag, an oral TPO mimetic taken once daily for about 6 months, stimulates residual HSCs and raises both overall (~80%) and complete (~50%) response rates when added to horse ATG — making it FDA-approved standard of care in 2018; hepatotoxicity is its key adverse effect. Granulocyte recovery is generally apparent within 2 months.

Long-term course after IST: relapse is frequent, often as cyclosporine or eltrombopag is tapered, and most (not all) relapses respond to reinstituted therapy; some patients become dependent on ongoing cyclosporine or eltrombopag. Clonal evolution — new cytogenetic abnormalities, MDS, or leukemia — occurs in ~10–15% of patients over a decade; repeat marrow examination is warranted with any unfavorable change in counts. Patients who fail IST can still be salvaged with HSCT.

Supportive care bridges patients to definitive therapy: prompt empiric broad-spectrum antibiotics for fever with severe neutropenia (add antifungal coverage for persistent fever), prophylactic platelet transfusions to maintain platelets >10,000/μL, RBC transfusion for symptomatic anemia (typically hemoglobin ~70 g/L, higher with cardiopulmonary disease), and iron chelation after ~50 transfusions to prevent secondary iron overload. Avoid aspirin and NSAIDs in thrombocytopenic patients. EPO and G-CSF are not effective treatments for the marrow failure itself.

Pure Red Cell Aplasia

Pure red cell aplasia (PRCA) is a single-lineage marrow failure characterized by normocytic or macrocytic anemia with decreased reticulocytes and absent or markedly decreased erythrocyte precursors in the bone marrow, while leukocyte and platelet counts remain normal. In adults, PRCA is usually acquired; the identical congenital syndrome, Diamond-Blackfan anemia, presents at birth or in early childhood (ribosomal protein gene mutations; often glucocorticoid-responsive) and is a pediatric diagnosis.

Causes and Associations

Parvovirus B19

Parvovirus B19 is directly cytotoxic to erythrocyte precursors (it enters erythroid progenitors via the erythrocyte P antigen). In immunocompetent hosts the infection is transient (2–3 weeks) and rarely causes clinically significant anemia, because the brief halt in red cell production is well tolerated. Two settings change this calculus: patients with chronic hemolysis (e.g., sickle cell disease), who depend on accelerated erythropoiesis, can suffer a dramatic transient aplastic crisis with abrupt anemia and reticulocytopenia; and immunocompromised patients, who cannot mount neutralizing antibodies, may develop sustained viremia and prolonged anemia that responds to intravenous immune globulin to hasten viral clearance. The marrow classically shows giant pronormoblasts; diagnosis in immunodeficient patients requires detection of viral DNA (serologic antibody tests may be falsely negative).

Thymoma, LGL Leukemia, and Other Associations

Some patients with PRCA harbor an occult thymoma — image the mediastinum in every case; excision is indicated, although the anemia does not necessarily improve with surgery. Large granular lymphocyte (LGL) leukemia, a T-cell lymphoproliferative disorder, is an important association and can be identified by flow cytometry of peripheral blood. Red cell aplasia can also complicate CLL, and anti-EPO neutralizing antibodies (from subcutaneous EPO therapy) are a rare iatrogenic cause. For most acquired PRCA, T-cell–mediated suppression of erythropoiesis is the dominant immune mechanism.

Diagnosis and Treatment

Workup begins with history (including drug exposure), examination, and routine laboratories, plus imaging to exclude thymoma and parvovirus B19 DNA testing where indicated. Confirming the diagnosis, however, requires histology:

Treatment is directed at the cause when one is found: IVIG for persistent parvovirus B19 infection, discontinuation of an implicated drug, thymectomy for thymoma. Red cell aplasia is compatible with long-term survival on supportive care alone (erythrocyte transfusions plus iron chelation), but the majority of patients with acquired PRCA respond favorably to immunosuppression — glucocorticoids, cyclosporine, ATG, azathioprine, or cyclophosphamide.